Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Acceptability, Quality of Care, Patient Satisfaction, and Cost-effectiveness of Monitoring Provided by Nurses or Physicians for People Using HIV Pre-exposure Prophylaxis (PREVI)

2. august 2026 oppdatert av: Assistance Publique - Hôpitaux de Paris

An Open-label Randomized Trial Evaluating the Acceptability, Quality of Care, Patient Satisfaction, and Cost-effectiveness of Monitoring Provided by Nurses or Physicians for People Using HIV Pre-exposure Prophylaxis

Assess the quality of care and the satisfaction of patients and caregivers when the monitoring of people on HIV pre-exposure prophylaxis (PrEP) is provided by nurses instead of physicians

Studieoversikt

Detaljert beskrivelse

The HIV/AIDS epidemic remains uncontrolled in France, with approximately 5,000 to 6,000 new cases reported each year. Since January 2016, HIV pre-exposure prophylaxis (PrEP)-which involves taking a single oral tablet containing two antiretroviral drugs-has been available in France. The effectiveness of this PrEP has been demonstrated, with a relative reduction in HIV incidence of nearly 97% when PrEP is taken correctly.

However, only nearly 50,000 people are using PrEP in France in 2024, which is far short of the targets needed to control the epidemic. Indeed, the population of men who have sex with men (MSM) at risk of HIV infection is estimated at over 200,000, and the number of heterosexuals on PrEP is negligible, even though 40% of new HIV diagnoses involve heterosexuals from countries with high prevalence (Sub-Saharan Africa).

Furthermore, these 50,000 people on PrEP represent only 64% of the >120,000 people who have started PrEP since 2016, indicating that many have discontinued this prophylaxis over time. One of the challenges in implementing PrEP stems from the small number of trained hospital and primary care physicians and their limited time availability to provide a PrEP care.

Since 2022, PrEP training programs in medical settings, involving nurses, have been implemented to train them to monitore people on PrEP. This involvement of nurses would help increase the availability of PrEP, free up doctors' time for complex cases, and enhance the value of nursing work.

However, there has been no evaluation of this care provided by nurses to people on PrEP in terms of quality, acceptability, satisfaction among people on PrEP, nurses, and doctors, or its cost-effectiveness.

The aim of our study is therefore to assess whether the care provided to subjects on PrEP by these nurses is as good, well-accepted, and satisfactory for subjects and caregivers as it would be if the care were provided solely by physicians.

Studietype

Intervensjonell

Registrering (Antatt)

504

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Male sex assigned at birth, aged ≥ 18 years
  • Individual at risk of HIV infection
  • Currently receiving PrEP care and willing to continue follow-up in a hospital setting
  • Receiving care at a hospital setting by a physician and not objecting to follow-up by a nurse
  • Having received complete information about the study and having provided a free written informed consent
  • Affiliated with a social security system (beneficiary or entitled individual) or covered by State Medical Aid (AME).

Exclusion Criteria:

  • Individual with confirmed HIV infection
  • Currently receiving nurse care in a hospital setting
  • Having renal impairment (creatinine clearance < 60 mL/min)
  • Unable to provide informed consent
  • Not affiliated with a social security system or not covered by State Medical Aid (AME)
  • Under legal guardianship or curatorship
  • Deprived of liberty by judicial or administrative decision, or individuals receiving psychiatric care under Article L1121-6 of the French Public Health Code

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Follow-up visits for PrEP prescription conducted by a physician.
Monitoring of PrEP by physicians
Eksperimentell: Follow-up visits for PrEP prescription conducted by a nurse under the same conditions.
Monitoring of PrEP by nurses

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Compliance to PrEP
Tidsramme: Up to 12 months

Compliance to PrEP is defined by a composite criterion comprising:

  • Presence at scheduled follow-up visits at 0, 6, and 12 months AND
  • Undergoing an HIV screening test before each visit to allow for the prescription of PrEP if the result is negative (+/-14 days) AND
  • Prescription of PrEP at each visit
Up to 12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Occurrence of sexually transmitted infection (STI)
Tidsramme: At baseline
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
At baseline
Occurrence of sexually transmitted infection (STI)
Tidsramme: At 6 months
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
At 6 months
Occurrence of sexually transmitted infection (STI)
Tidsramme: At 12 months
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
At 12 months
Tolerability of PrEP
Tidsramme: At baseline
Plasma creatine level
At baseline
Tolerability of PrEP
Tidsramme: At 6 months
Plasma creatine level
At 6 months
Tolerability of PrEP
Tidsramme: At 12 months
Plasma creatine level
At 12 months
PrEP adherence
Tidsramme: At 12 months
Number of patient visits completed during the year and Tenofovir diphosphate concentrations
At 12 months
Treatment acceptability among participants
Tidsramme: Up to 12 months
Number of participants who discontinued follow-up and reasons for discontinuation
Up to 12 months
Incidence of HIV infection
Tidsramme: Up to 12 months
HIV infection during follow up (positive serology or HIV RNA)
Up to 12 months
Cost of care
Tidsramme: Up to 12 months
From the perspectives of the healthcare system, patients, and health insurance : Incremental or decremental cost-effectiveness ratio (Cost per patient, Time spent in consultations, Number of prescribed labs and tests, and Number and duration of any hospitalizations…)
Up to 12 months
Patient and caregiver satisfaction
Tidsramme: At 12 months
Focus groups
At 12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. september 2026

Primær fullføring (Antatt)

1. september 2028

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

6. juli 2026

Først innsendt som oppfylte QC-kriteriene

6. juli 2026

Først lagt ut (Faktiske)

10. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere